Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurology and primary care clinicians (MD/DO/NP/PA) engaged in the care of patients with Alzheimer’s disease.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Identify mild cognitive impairment and early Alzheimer’s disease with the help of screening tools, biomarkers, and neuroimaging techniques
• Integrate approved and emerging anti-amyloid β therapies for the treatment of mild cognitive impairment and early-stage Alzheimer’s disease

Activity Description

Alzheimer’s disease (AD) is a growing public health concern, and as the aging population rapidly increases, so too does the number of individuals affected by AD. The recent availability of therapy for mild cognitive impairment (MCI) and early-stage AD has increased the need for early screening. In this uniquely designed, reflective activity, learners are presented with 2 cases related to AD and challenged to think about how the patients could have been better assessed/managed. A multidisciplinary discussion between a primary care physician (PCP) and neurologist will combine elements of cognitive assessment, proper screening and referral, and early management to demonstrate the critical relationship PCPs and neurologists have in identifying and managing patients with MCI/early-stage AD.

Chair

Marwan Noel Sabbagh, MD, FAAN
Professor, Neurology
Barrow Neurological Institute
Phoenix, AZ

Faculty

Warren A. Jones, MD, FAAFP
Professor Emeritus, University of Mississippi Medical Center
Chief Health Officer, The Jones Group of Mississippi
Jackson, MS

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Warren A. Jones, MD, FAAFP, has no relevant financial relationship(s) with ineligible companies to disclose.

Marwan Noel Sabbagh, MD, FAAN, has relevant financial relationships with Acadia Pharmaceuticals, Alzheon, Biogen, Cortexyme, Eisai, Eli Lilly, Genentech, KeifeRx, Qynapse, Renew Research, T3D Therapeutics (Consultant); Athira, Brain Health Inc., Cognoptix, NeuroTau, Optimal Cognitive Health Company, TransDermix, uMethod Health, Versanum (Stock/Shareholder); Clinical Options, Health and Wellness Partners (Speaker/Speaker’s Bureau); Humanix (Other: Royalties).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed Credits
The AAFP has reviewed The Increasingly Vital Role of Early Alzheimer’s Disease Diagnosis & Treatment in Averting the Amyloid Tipping Point and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 04/15/2022 to 04/14/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurology and primary care clinicians (MD/DO/NP/PA) engaged in the care of patients with Alzheimer’s disease.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Identify mild cognitive impairment and early Alzheimer’s disease with the help of screening tools, biomarkers, and neuroimaging techniques
• Integrate approved and emerging anti-amyloid β therapies for the treatment of mild cognitive impairment and early-stage Alzheimer’s disease

Activity Description

Alzheimer’s disease (AD) is a growing public health concern, and as the aging population rapidly increases, so too does the number of individuals affected by AD. The recent availability of therapy for mild cognitive impairment (MCI) and early-stage AD has increased the need for early screening. In this uniquely designed, reflective activity, learners are presented with 2 cases related to AD and challenged to think about how the patients could have been better assessed/managed. A multidisciplinary discussion between a primary care physician (PCP) and neurologist will combine elements of cognitive assessment, proper screening and referral, and early management to demonstrate the critical relationship PCPs and neurologists have in identifying and managing patients with MCI/early-stage AD.

Chair

Marwan Noel Sabbagh, MD, FAAN
Professor, Neurology
Barrow Neurological Institute
Phoenix, AZ

Faculty

Warren A. Jones, MD, FAAFP
Professor Emeritus, University of Mississippi Medical Center
Chief Health Officer, The Jones Group of Mississippi
Jackson, MS

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty

Warren A. Jones, MD, FAAFP, has no relevant financial relationship(s) with ineligible companies to disclose.

Marwan Noel Sabbagh, MD, FAAN, has relevant financial relationships with Acadia Pharmaceuticals, Alzheon, Biogen, Cortexyme, Eisai, Eli Lilly, Genentech, KeifeRx, Qynapse, Renew Research, T3D Therapeutics (Consultant); Athira, Brain Health Inc., Cognoptix, NeuroTau, Optimal Cognitive Health Company, TransDermix, uMethod Health, Versanum (Stock/Shareholder); Clinical Options, Health and Wellness Partners (Speaker/Speaker’s Bureau); Humanix (Other: Royalties).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed Credits
The AAFP has reviewed The Increasingly Vital Role of Early Alzheimer’s Disease Diagnosis & Treatment in Averting the Amyloid Tipping Point and deemed it acceptable for up to 0.50 Enduring Materials, Self-Study AAFP Prescribed credits. Term of Approval is from 04/15/2022 to 04/14/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAFP Prescribed credit is accepted by the American Medical Association as equivalent to AMA PRA Category 1 Credit(s)™ toward the AMA Physician’s Recognition Award. When applying for the AMA PRA, Prescribed credit earned must be reported as Prescribed, not as Category 1.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 75% or higher on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

There is no fee to participate.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING
FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent educational grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurologists, pediatric neurologists, physical medicine and rehabilitation specialists, orthopedists, nurses (RN/NP/APN), PAs, and other clinicians involved in the care of patients with spinal muscular atrophy (SMA).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Select individualized disease-modifying therapy for patients with spinal muscular atrophy (SMA)
• Integrate the unique roles of the interprofessional care team in concert with consensus guidelines and best practice recommendations for management of SMA

Activity Description

Spinal muscular atrophy (SMA) is a devastating diagnosis that is often delivered at a very tender, young age. Not too long ago, providers had nothing to treat patients with SMA beyond supportive therapies. However, now there are 3 different disease-modifying therapies to consider. We have polled clinicians across the country to find out what challenges they are met with when managing SMA in their patients. In this activity, our faculty discuss their approach to treatment for 2 of these challenging cases, with a focus on when to initiate therapy.

Chair

Diana P. Castro, MD
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX

Faculty

Susan Apkon, MD
Fischahs Chair, Pediatric Rehabilitation
Chief, Department of Rehabilitation
Children’s Hospital Colorado
Professor and Vice Chair, Department of Physical Medicine and Rehabilitation
University of Colorado School of Medicine
Aurora, CO

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN
Nurse Practitioner, Pediatrics
Philadelphia, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty
Susan Apkon, MD, has relevant financial relationships with AveXis/Novartis, Biogen, Sarepta Therapeutics, Scholar Rock (Grant/Research Support).

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, has relevant financial relationships with AveXis/Novartis, Biogen, PTC Pharmaceuticals (Advisor); AveXis/Novartis (Speaker/Speaker’s Bureau).

Diana P. Castro, MD, has relevant financial relationships with Biogen, Genentech, Novartis, SKR (Researcher).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Provided By

RMEI Medical Education, LLC

Target Audience

This activity is intended for neurologists, pediatric neurologists, physical medicine and rehabilitation specialists, orthopedists, nurses (RN/NP/APN), PAs, and other clinicians involved in the care of patients with spinal muscular atrophy (SMA).

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Select individualized disease-modifying therapy for patients with spinal muscular atrophy (SMA)
• Integrate the unique roles of the interprofessional care team in concert with consensus guidelines and best practice recommendations for management of SMA

Activity Description

Spinal muscular atrophy (SMA) is a devastating diagnosis that is often delivered at a very tender, young age. Not too long ago, providers had nothing to treat patients with SMA beyond supportive therapies. However, now there are 3 different disease-modifying therapies to consider. We have polled clinicians across the country to find out what challenges they are met with when managing SMA in their patients. In this activity, our faculty discuss their approach to treatment for 2 of these challenging cases, with a focus on when to initiate therapy.

Chair

Diana P. Castro, MD
Associate Professor, Pediatrics and Neurology
University of Texas Southwestern
Children’s Health
Dallas, TX

Faculty

Susan Apkon, MD
Fischahs Chair, Pediatric Rehabilitation
Chief, Department of Rehabilitation
Children’s Hospital Colorado
Professor and Vice Chair, Department of Physical Medicine and Rehabilitation
University of Colorado School of Medicine
Aurora, CO

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN
Nurse Practitioner, Pediatrics
Philadelphia, PA

Disclosure of Financial Relationships

RMEI Medical Education, LLC (RMEI) requires instructors, planners, managers, and others in control of educational content to disclose all their financial relationships with ineligible companies over the previous 24 months. All identified financial relationships are thoroughly vetted and mitigated according to RMEI policy.

Faculty
Susan Apkon, MD, has relevant financial relationships with AveXis/Novartis, Biogen, Sarepta Therapeutics, Scholar Rock (Grant/Research Support).

Vanessa Battista, DNP, MBA, RN, MS, CPNP-PC, CHPPN, has relevant financial relationships with AveXis/Novartis, Biogen, PTC Pharmaceuticals (Advisor); AveXis/Novartis (Speaker/Speaker’s Bureau).

Diana P. Castro, MD, has relevant financial relationships with Biogen, Genentech, Novartis, SKR (Researcher).

All of the relevant financial relationships listed for these individuals have been mitigated according to RMEI policies.

Planners and Managers
RMEI Medical Education, LLC planners and managers have no relevant financial relationship(s) with ineligible companies to disclose.

Joint Accreditation Statement

In support of improving patient care, RMEI Medical Education, LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Designation of Credit

Physician Continuing Medical Education
RMEI Medical Education, LLC designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 0.25 contact hour(s).

Interprofessional Continuing Education
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Instructions for Receiving Credit

In order to receive credit, participants must review the activity content and successfully complete both the post-test and evaluation. A statement of credit will be available to print immediately. You must score 100% on the post-test to receive credit for this activity. If you have questions about this activity, please contact RMEI at contact@rmei.com.

Users must:

• Read the learning objectives and faculty disclosures
• Participate in the activity
• Complete the activity evaluation and attest to credit

There is no fee for this educational activity.

Your Feedback is Important!

COMPLETE THE EVALUATION FORM AND YOU WILL BE ENTERED INTO A DRAWING FOR A $100* AMAZON GIFT CARD!
*The expense for this gift card is solely funded by RMEI Medical Education, LLC.
No supporter funding was used for the expense of this gift card.

Rules and Regulations
This sweepstakes is managed by RMEI Medical Education, LLC (RMEI), a jointly accredited provider. The winner will be selected via automated random drawing on a quarterly basis from among all eligible entries and notified through the contact information provided. In accordance with our privacy policy, we do not share your information with any third parties. By entering the sweepstakes, you grant RMEI permission to use your e-mail address to reach you for notification and prize fulfillment. Only individuals who complete the evaluation forms and provide contact information will be eligible to win. Open to those who have a US postal address and who are 18 years or older. Only one prize per person and per household will be awarded. The prize will be a $100 Amazon gift card.

Statement of Commercial Support

This activity is supported by an independent medical education grant from Biogen MA, Inc.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Activity Details

Accredited By

Target Audience

Healthcare professionals who care for patients with multiple sclerosis, including neurologists, primary care physicians, physician assistants, nurse practitioners, and other supporting clinicians

Learning Objectives

1. Understand the pharmacology science of fumarate-based therapeutics and the importance of drugs vs. pro-drugs bioavailability
2. Review the safety and efficacy data for novel oral fumarate-based therapeutics
3. Discuss strategies to increase patient adherence to treatment, including adverse events, route of administration, and financial impact
4. Review clinical applications of novel oral fumarate-based therapeutics for the treatment of Relapsing MS, CIS, and Active Secondary MS, including switching therapies

Activity Description

This CME/CE webcast, chaired by Fred D. Lublin, MD, will analyze current best practices for utilizing fumarate-based therapeutics to improve outcomes in patients with multiple sclerosis (MS). The expert faculty will first review the mechanism of action and targets of fumarates in the MS treatment landscape. Following, current trial data of fumarate-based therapeutics in MS will be reviewed and clinical implications debated in an interactive panel format. The faculty will conclude with a discussion of clinical strategies for fumarate-based therapeutics, analyzing pros and cons of therapy while considering hot topics such as vaccination status and future considerations.

Statement of Educational Need

Healthcare team members need to understand the most recent clinical trial data regarding advances in fumarate-based therapeutics to improve outcomes in patients with multiple sclerosis

Agenda

1. The Pharmacology Science Review of Fumarate-based Therapeutics and the Importance of Bioavailability: Drugs vs. Pro-drugs
2. Clinical Trial Review for Novel Oral Fumarate-based Therapeutics to Treat Patients with MS
3. Increasing Patient Adherence to Treatment by Mitigating Adverse Events and Patient Education
4. Developing Clinical Treatment Plans for Novel Oral Fumarate-based Therapeutics to Improve Outcomes in Patients with Relapsing MS, CIS, and Active Secondary MS, Including Switching Therapies
5. Faculty Panel Discussion

Course Chair

Fred D. Lublin, MD
Saunders Family Professor of Neurology Director
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, New York

Faculty

Patricia Coyle, MD
Professor and Vice Chair (Clinical Affairs)
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York

Stephen Krieger, MD
Professor of Neurology
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Department of Neurology
Icahn School of Medicine at Mount Sinai
New York, New York

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Fred D. Lublin, MD
Consultant/Advisor: Acorda Therapeutics; Actelion Pharmaceuticals US, Inc.; Apitope; Atara Biotherapeutics; Avotres Inc.; Banner Life Sciences; Biogen; Brainstorm Cell Therapeutics; Bristol Myers Squibb; Celgene Corporation; EMD Serono, Inc.; Entelexo Biotherapeutics; Genentech, Inc.; GW Pharmaceuticals; Horizon Therapeutics; Immunic Therapeutics; Janssen Global Services, LLC; Jazz Pharmaceuticals; Labcorp; Mapi-Pharma Ltd.; MedDay Pharmaceuticals; Medimmune, LLC; Mylan; Neurogene; Novartis AG; Orion Biotechnology; Receptos; Roche; Sanofi Genzyme; Teva Pharmaceuticals; TG Therapeutics; Viela Bio, Inc.
Grant/Research Support: Actelion Pharmaceuticals US, Inc.; Biogen; Brainstorm Cell Therapeutics; Novartis AG; Sanofi Genzyme
Speaker’s Bureau: Sanofi Genzyme
Stock Options: Avotres Inc.

Patricia Coyle, MD
Consultant/Advisor: Accordant, A CVS Caremark Company; Alexion Pharmaceuticals, Inc.; Bayer AG; Biogen; Bristol Myers Squibb; Celgene Corporation; EMD Serono, Inc.; Genentech, Inc.; GlaxoSmithKline; Horizon Therapeutics; Janssen Global Services, LLC; Novartis AG; Roche; Sanofi Genzyme; TG Therapeutics; Viela Bio, Inc.
Grant/Research Support: Actelion Pharmaceuticals US, Inc.; Alkermes; Corrona LLC; Genentech, Inc.; MedDay Pharmaceuticals; Novartis AG; Roche; Sanofi Genzyme
Speaker’s Bureau: Biogen; Janssen Global Services, LLC

Stephen Krieger, MD
Consultant/Advisor: Biogen; EMD Serono, Inc.; Genentech, Inc.; Mallinckrodt Pharmaceuticals; MedDay Pharmaceuticals; Novartis AG; Sanofi Genzyme; Teva Pharmaceuticals; TG Therapeutics
Grant/Research Support: Biogen; Novartis AG
Speaker’s Bureau: Biogen; EMD Serono, Inc.; Genentech, Inc.; Novartis AG

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour(s), including 1.0 Pharmacotherapeutic Contact Hour(s) (Provider # P0491).

Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

1. Read the learning objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions.
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
   • CME and CNE credit will be issued an appropriate certificate of completion.
   • Others may request a “certificate of completion”.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME and/or CNE credit).
6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from Banner Life Sciences.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Banner Life Sciences do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.

Activity Details

Accredited By

Target Audience

Healthcare professionals who care for patients with multiple sclerosis, including neurologists, primary care physicians, physician assistants, nurse practitioners, and other supporting clinicians

Learning Objectives

1. Understand the pharmacology science of fumarate-based therapeutics and the importance of drugs vs. pro-drugs bioavailability
2. Review the safety and efficacy data for novel oral fumarate-based therapeutics
3. Discuss strategies to increase patient adherence to treatment, including adverse events, route of administration, and financial impact
4. Review clinical applications of novel oral fumarate-based therapeutics for the treatment of Relapsing MS, CIS, and Active Secondary MS, including switching therapies

Activity Description

This CME/CE webcast, chaired by Fred D. Lublin, MD, will analyze current best practices for utilizing fumarate-based therapeutics to improve outcomes in patients with multiple sclerosis (MS). The expert faculty will first review the mechanism of action and targets of fumarates in the MS treatment landscape. Following, current trial data of fumarate-based therapeutics in MS will be reviewed and clinical implications debated in an interactive panel format. The faculty will conclude with a discussion of clinical strategies for fumarate-based therapeutics, analyzing pros and cons of therapy while considering hot topics such as vaccination status and future considerations.

Statement of Educational Need

Healthcare team members need to understand the most recent clinical trial data regarding advances in fumarate-based therapeutics to improve outcomes in patients with multiple sclerosis

Agenda

1. The Pharmacology Science Review of Fumarate-based Therapeutics and the Importance of Bioavailability: Drugs vs. Pro-drugs
2. Clinical Trial Review for Novel Oral Fumarate-based Therapeutics to Treat Patients with MS
3. Increasing Patient Adherence to Treatment by Mitigating Adverse Events and Patient Education
4. Developing Clinical Treatment Plans for Novel Oral Fumarate-based Therapeutics to Improve Outcomes in Patients with Relapsing MS, CIS, and Active Secondary MS, Including Switching Therapies
5. Faculty Panel Discussion

Course Chair

Fred D. Lublin, MD
Saunders Family Professor of Neurology Director
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
New York, New York

Faculty

Patricia Coyle, MD
Professor and Vice Chair (Clinical Affairs)
Director, MS Comprehensive Care Center
Stony Brook University Medical Center
Stony Brook, New York

Stephen Krieger, MD
Professor of Neurology
The Corinne Goldsmith Dickinson Center for Multiple Sclerosis
Department of Neurology
Icahn School of Medicine at Mount Sinai
New York, New York

Disclosures of Conflict of Interest

It is the policy of AcademicCME that all faculty, instructors, and planners disclose real or apparent conflicts of interest relating to the topics of this educational activity.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:

Fred D. Lublin, MD
Consultant/Advisor: Acorda Therapeutics; Actelion Pharmaceuticals US, Inc.; Apitope; Atara Biotherapeutics; Avotres Inc.; Banner Life Sciences; Biogen; Brainstorm Cell Therapeutics; Bristol Myers Squibb; Celgene Corporation; EMD Serono, Inc.; Entelexo Biotherapeutics; Genentech, Inc.; GW Pharmaceuticals; Horizon Therapeutics; Immunic Therapeutics; Janssen Global Services, LLC; Jazz Pharmaceuticals; Labcorp; Mapi-Pharma Ltd.; MedDay Pharmaceuticals; Medimmune, LLC; Mylan; Neurogene; Novartis AG; Orion Biotechnology; Receptos; Roche; Sanofi Genzyme; Teva Pharmaceuticals; TG Therapeutics; Viela Bio, Inc.
Grant/Research Support: Actelion Pharmaceuticals US, Inc.; Biogen; Brainstorm Cell Therapeutics; Novartis AG; Sanofi Genzyme
Speaker’s Bureau: Sanofi Genzyme
Stock Options: Avotres Inc.

Patricia Coyle, MD
Consultant/Advisor: Accordant, A CVS Caremark Company; Alexion Pharmaceuticals, Inc.; Bayer AG; Biogen; Bristol Myers Squibb; Celgene Corporation; EMD Serono, Inc.; Genentech, Inc.; GlaxoSmithKline; Horizon Therapeutics; Janssen Global Services, LLC; Novartis AG; Roche; Sanofi Genzyme; TG Therapeutics; Viela Bio, Inc.
Grant/Research Support: Actelion Pharmaceuticals US, Inc.; Alkermes; Corrona LLC; Genentech, Inc.; MedDay Pharmaceuticals; Novartis AG; Roche; Sanofi Genzyme
Speaker’s Bureau: Biogen; Janssen Global Services, LLC

Stephen Krieger, MD
Consultant/Advisor: Biogen; EMD Serono, Inc.; Genentech, Inc.; Mallinckrodt Pharmaceuticals; MedDay Pharmaceuticals; Novartis AG; Sanofi Genzyme; Teva Pharmaceuticals; TG Therapeutics
Grant/Research Support: Biogen; Novartis AG
Speaker’s Bureau: Biogen; EMD Serono, Inc.; Genentech, Inc.; Novartis AG

Accreditation Statement

In support of improving patient care, AcademicCME is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. This activity was planned by and for the healthcare team.

Designation of Credit

AcademicCME designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™.

AcademicCME designates this enduring material for a maximum of 1.0 CNE Contact Hour(s), including 1.0 Pharmacotherapeutic Contact Hour(s) (Provider # P0491).

Clinicians should claim only the credit commensurate with the extent of their participation in the activity.

Method of Participation

In order to claim credit, participants must complete the following:

1. Read the learning objectives, accreditation information, and faculty disclosures at the beginning of this activity.
2. Complete the Pre-Activity Questions.
3. Read or Review the activity content.
4. Complete the Post-Activity Test Questions and Evaluation.
   • CME and CNE credit will be issued an appropriate certificate of completion.
   • Others may request a “certificate of completion”.
5. Learners who receive a grade of 70% or better on the Post-Activity Test Questions and complete the Evaluation will receive appropriate credit as indicated (CME and/or CNE credit).
6. Learners should claim only the credit commensurate with the extent of their participation in the activity.

Statement of Commercial Support

This activity has been supported by an independent educational grant from Banner Life Sciences.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. AcademicCME and Banner Life Sciences do not recommend the use of any agent outside of the labeled indications.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Contact Information for Questions About the Activity

For all CME/CE inquiries or special needs, please contact admin@academiccme.com or 610-687-3300.